The HDDC Pilot-Feasibility (P/F) Grant Program is a centerpiece of HDDC activities with an important impact on future advances in digestive disease research. The P/F Program provides funding ($25 K for 1 year) that primarily targets young investigators in the process of establishing their independent research careers, but also allows established investigators to initiate innovative and promising pilot projects that could lead to substantial funding for new lines of research relevant to digestive diseases.
The Specific Aims of the HDDC P/F Program are: 1. To support and encourage young and mentored investigators in digestive disease-related research who have not previously held independent awards (Type I Awards). 2. To entice accomplished investigators from other fields who are not currently focused on digestive diseases to apply new concepts and technical approaches to the digestive tract (Type II awards). 3. To enable established investigators already working in digestive disease-related research to initiate a substantial, innovative change in the direction of their research (Type III awards). The HDDC selects these projects through a rigorous multi-step process modeled on NIH study sections. Proposals are scored on the basis of innovation, scientific merit and the potential for future independent funding in digestive disease research. The success rate of PF awardees in obtaining subsequent grant support has been outstanding. Since 2006 45 investigators have been supported by HDDC P/F grants including 4 current grantees. Of the 41 previous PF awardees, 39 (95 %) subsequently won independent grant funding and all previous grantees but one are still engaged in digestive disease-related research.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
2P30DK034854-31
Application #
8971195
Study Section
Special Emphasis Panel ()
Project Start
Project End
Budget Start
2015-12-01
Budget End
2016-11-30
Support Year
31
Fiscal Year
2016
Total Cost
$191,725
Indirect Cost
$77,000
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Nudel, K; Zhao, X; Basu, S et al. (2018) Genomics of Corynebacterium striatum, an emerging multidrug-resistant pathogen of immunocompromised patients. Clin Microbiol Infect 24:1016.e7-1016.e13
Biswas, Amlan; Shouval, Dror S; Griffith, Alexandra et al. (2018) WASP-mediated regulation of anti-inflammatory macrophages is IL-10 dependent and is critical for intestinal homeostasis. Nat Commun 9:1779
Han, Lichy; Maciejewski, Mateusz; Brockel, Christoph et al. (2018) A probabilistic pathway score (PROPS) for classification with applications to inflammatory bowel disease. Bioinformatics 34:985-993
Fishman, Laurie N; Kearney, Jennifer; DeGroote, Maya et al. (2018) Creation of Experience-based Celiac Benchmarks: The First Step in Pretransition Self-management Assessment. J Pediatr Gastroenterol Nutr 67:e6-e10
Kamareddine, Layla; Robins, William P; Berkey, Cristin D et al. (2018) The Drosophila Immune Deficiency Pathway Modulates Enteroendocrine Function and Host Metabolism. Cell Metab 28:449-462.e5
Iyer, Shankar S; Gensollen, Thomas; Gandhi, Amit et al. (2018) Dietary and Microbial Oxazoles Induce Intestinal Inflammation by Modulating Aryl Hydrocarbon Receptor Responses. Cell 173:1123-1134.e11
McSweeney, Maireade E; Kerr, Jessica; Amirault, Janine et al. (2018) Preoperative Evaluation Is Not Predictive of Transpyloric Feeding Conversion in Gastrostomy-dependent Pediatric Patients. J Pediatr Gastroenterol Nutr 66:887-892
Thiagarajah, Jay R; Kamin, Daniel S; Acra, Sari et al. (2018) Advances in Evaluation of Chronic Diarrhea in Infants. Gastroenterology 154:2045-2059.e6
Masuyer, Geoffrey; Zhang, Sicai; Barkho, Sulyman et al. (2018) Structural characterisation of the catalytic domain of botulinum neurotoxin X - high activity and unique substrate specificity. Sci Rep 8:4518
Xenakis, Jason J; Howard, Emily D; Smith, Kalmia M et al. (2018) Resident intestinal eosinophils constitutively express antigen presentation markers and include two phenotypically distinct subsets of eosinophils. Immunology 154:298-308

Showing the most recent 10 out of 869 publications